Carmen A. Banuelos
Vancouver, BC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Drugging the intrinsically disordered transactivation domain of androgen receptor.
Journal: Signal transduction and targeted therapy
Published: October 07, 2025
Rational optimization of a transcription factor activation domain inhibitor.
Journal: Nature structural & molecular biology
Published: November 21, 2022
Structure-Activity Relationships for the Marine Natural Product Sintokamides: Androgen Receptor N-Terminus Antagonists of Interest for Treatment of Metastatic Castration-Resistant Prostate Cancer.
Journal: Journal of natural products
Published: October 30, 2020
Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants.
Journal: Cancers
Published: June 17, 2020
An imaging agent to detect androgen receptor and its active splice variants in prostate cancer.
Journal: JCI insight
Published: August 16, 2016
Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain.
Journal: The Journal of biological chemistry
Published: April 22, 2016
Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 01, 2015
Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 06, 2015
N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy.
Journal: Molecular oncology
Published: August 05, 2014
Characterization of niphatenones that inhibit androgen receptor N-terminal domain.
Journal: PloS one
Published: June 18, 2014
An androgen receptor N-terminal domain antagonist for treating prostate cancer.
Journal: The Journal of clinical investigation
Published: August 17, 2012
Last Updated: 09/26/2026